Targeted Delivery Services

The discovery of the targeting module has been emphasized for active targeting payload delivery system and non-invasive imaging. With years of experience and high-end technologies in small molecules targeting research, Creative Biolabs has successfully developed a series of innovative and diversified technique platforms to supply modules specifically binding to different targets, including the modules specifically targeting diseases, targeting organs or tissues, targeting subcellular organelles, targeting microorganisms.

Although X-ray, low-dose spiral computed tomography (CT) and modalities such as surgery, chemotherapy, radiation therapy or combination treatment have been commonly used clinically for some disease detection and treatment of cancer, the exposure to radiation after repeated scanning poses a serious health risk. Thus, more specific and safer diagnostics is needed and modules-mediated delivery systems have sprung up in the various field.

As an extremely important part of the delivery system, the modules could be utilized to provide feasibility of therapeutic targets for the development of potential therapeutics. Moreover, the modules could be conjugated to apply as an imaging probe with various molecules such as iron oxide and fluorescent agent. Furthermore, the modules could be utilized to find and prove a diagnostic biomarker and tethered to carriers through physical/chemical conjugation for the development of drug delivery systems. Therefore, modules are versatile molecules that can be potentially applied to diverse creation of therapeutic and diagnostics.

Fig.1 Schematic of a nanoparticle platform for drug delivery.

Examples

• Paclitaxel does not reach high concentrations in brain tumor tissue following normal intravenous injection, but GRN1005, a novel peptide-drug conjugate composed of paclitaxel covalently linked to a peptide targeting the low-density lipoprotein receptor-related protein 1 (LRP-1), can penetrate the blood-brain barrier (BBB) and has acted in both the brain and other metastatic sites.


• Many targeting modules with the diagnostic and therapeutic utility that possess broad subtype specificity for diseases such as SCLC and non-small cell lung cancer (NSCLC) were identified through phage display technique. These modules have the potential to guide a wide variety of tailored theranostic agents for targeting therapeutics, non-invasive imaging, or clinical detection of SCLC and NSCLC.

Fig.2 Mechanism of iRGD in tumor penetration. (Yin, 2017)

Encapsulation of anticancer drugs or other payloads in carriers, such as liposomes, markedly improves their pharmacokinetic profiles by increasing the drug payload, prolonging serum half-life, and reducing exposure to normal tissues. PEGylated liposome, albumin, and other carriers in module delivery systems are currently available for targeted delivery services.

Advantages of Our Services

Modules have significant potential to be incorporated into effective theranostic strategies, such as tailored targeting therapy, companion diagnostics, and non-invasive imaging. Hence, modules are meaningful for translational and precision medicine. Creative Biolabs offers customized services based on multivalent targeting strategies that can provide sufficient avidity and enhanced effective association to overcome the low affinity of each monovalent module.

Features of Our Modules

• Chemically modified to alter affinity, charge, hydrophobicity, stability, solubility....
• Smaller than antibody-based targeting agents
• High specificities and affinities
• Display low toxicity profiles

Fig.3 Design of an ideal ligand-targeted drug.

What Can We do for You?

Targeting modules have been applied successfully in the fields of active targeting drug delivery and diagnostic imaging of various diseases. Creative Biolabs is a pioneer in the discovery of targeting molecules and a provider of customized services. Equipped with our well-established modules delivery systems, we can provide either individual targeting modules or different kinds of modules-cargo conjugates targeting a specific disease, cancer protein biomarker, and subcellular organelle. A wide spectrum of corresponding products is also available for your choice. If you are interested in our services or the services you wanted is not mentioned above, please don't hesitate to contact us for more information.

Reference

1. Yin, Hong, et al. "iRGD as a tumor‑penetrating peptide for cancer therapy." Molecular medicine reports 15.5 (2017): 2925-2930.

Our services are For Research Use Only. We do not provide services to individuals.